Lupus Nephritis

ORLANDO — In this video from ASN Kidney Week, Samir V. Parikh, MD, discusses the results of the AURORA 2 study.

In the 4 decades since 1976, the incidence and prevalence of lupus nephritis has increased among the population in Minnesota, according to data published in Arthritis Rheumatology.

SAN DIEGO — New drugs for the management of systemic lupus erythematosus and lupus nephritis may help bridge the gap of current unmet needs among patients, according to a speaker at the Congress of Clinical Rheumatology West.

Belimumab treatment and standard therapy caused greater kidney outcomes among East Asian patients with lupus nephritis compared with standard therapy alone.

Leflunomide is non-inferior to azathioprine in terms of safety and efficacy for lupus nephritis maintenance therapy, according to data published in the Annals of the Rheumatic Diseases.

Recent data has revealed a growing divide between rheumatologists and nephrologists in their therapeutic choices for patients with lupus nephritis, according to researchers from Spherix Global Insights.

The FDA has approved GlaxoSmithKline’s belimumab for the treatment of children with active lupus nephritis who are also receiving standard therapy, according to a company press release.

In the wake of the Supreme Court’s decision overturning Roe v. Wade, rheumatologists and rheumatology associations are voicing concern over what the loss of federal abortion protections could mean for patients.

Although commonly referred to as an “invisible illness,” lupus — and some of its treatments — can manifest in ways that are not only visible, but also heavily impact the daily lives of patients.

Although patients with lupus nephritis may require prednisone maintenance, attempts should be made to reduce their steroid doses, said a speaker at The Future of Systemic Lupus Erythematosus Diagnosis and Treatment meeting.